Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the impact of two different guidelines for monitoring labor progress on neonatal and maternal outcomes. The study compares the World Health Organizations Labour Care Guide LCG with standard delivery care in Sweden. The goal is to see if using the LCG can reduce adverse neonatal outcomes and lower the rate of intrapartum Cesarean sections. This study uses a multicenter, stepped-wedge cluster randomized design to explore these effects along with economic considerations and experiences related to childbirth. Participants will receive labor monitoring either according to the WHOs LCG guidelines or standard care. The study will involve multiple delivery units in Sweden, and women in active labor will be randomly assigned to either group as the new guidelines are gradually introduced. Alongside the main study periods, researchers will examine perinatal interventions, labor complications, and collect qualitative data through questionnaires, focus groups, and interviews with women, their partners, and healthcare providers. During participation, women and their partners will be asked about their childbirth experiences, while providers compliance and views on using the LCG will also be assessed. The study will track outcomes such as perinatal mortality, neonatal morbidity, cesarean section rates, and obstetric events like postpartum hemorrhage and labor duration. Data collection and follow-up will occur from 12 weeks up to 18 months after delivery, including economic evaluations and provider experiences to fully understand the effects of the labor monitoring methods.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
This observational study focuses on patients with ATTR amyloidosis, aiming to gather real-world data on their disease journeys before and after diagnosis. It seeks to describe patient characteristics, treatment patterns, and outcomes, including clinical, economic, and quality of life measures. The study also aims to better understand how ATTR amyloidosis presents and affects daily living. The study does not involve any interventions, as it is a retrospective analysis of existing data from multiple countries. It includes patients with various types of ATTR amyloidosis, such as cardiomyopathy, neuropathy, wild type, hereditary, and mixed phenotypes. Data collected cover the period from before diagnosis up to the end of follow-up, which can last up to 12 years. Participants medical records will be reviewed to assess healthcare resource use, clinical measurements like neuropathy impairment scores, and humanistic outcomes such as quality of life and activities of daily living. The study will evaluate hospitalizations, outpatient visits, emergency visits, transplant events, and mortality over time. This long-term data collection helps characterize disease impact and resource use for patients with ATTR amyloidosis.
Actively Recruiting
This research aims to evaluate ways to prevent hernia after loop ileostomy reversal in patients who have undergone rectal cancer surgery. A loop ileostomy is a temporary opening created during rectal cancer surgery that is later closed in a separate operation. Hernia, a weakening of the abdominal wall at the stoma site, can cause pain, discomfort, and serious complications, and its frequency after ileostomy reversal varies widely. This study compares the use of a protective mesh to standard closure methods to see if hernia rates can be reduced. Participants will be randomly assigned to one of two groups one group will receive reinforcement of the abdominal wall with a mesh called Ultrapro Advanced, placed behind the muscles the other group will have the stoma site closed using standard suturing without mesh. The study is double-blinded, meaning neither patients nor surgeons recording follow-up data know which treatment was given. Procedures and outcomes such as operation time, complications, hospital stay, pain, and infections will be carefully recorded. Participants will be monitored before and after surgery, including a 30-day follow-up visit with questionnaires and complication assessments by a doctor not involved in the surgery. One year after the cancer operationwhich generally occurs 6 to 9 months after ileostomy reversalpatients will have a CT scan with straining to check for hernia and complete questionnaires. Further follow-up with questionnaires and imaging will occur at three years. The study involves detailed tracking of post-surgical recovery and hernia development over several years.
Actively Recruiting
Researchers are evaluating the effects of a restrictive strategy for giving non-resuscitation fluids to adult patients with septic shock. This trial aims to compare a protocolized reduction of these fluids against usual care to assess both beneficial and harmful impacts on patients during intensive care. The study focuses on adults who meet specific septic shock criteria, including infection suspicion, elevated plasma lactate, and need for vasopressors. Participants are randomly assigned to one of two groups. In the experimental group, non-resuscitation fluids are given according to a strict protocol that starts within two hours of randomization and continues during the ICU stay, up to 90 days. This protocol includes guidelines about maintenance fluids, intravenous and enteral hydration, nutrition, glucose use, and medication concentration. The other group receives fluids according to local standard practices with some general guidelines. Both groups are monitored throughout their ICU admission. During the study, participants undergo regular assessments including survival status at 90 days, complications in the ICU, and number of days free from mechanical ventilation within 90 days. Researchers also evaluate cognitive function and health-related quality of life six months after inclusion. The trial uses triple masking and follows participants from enrollment through ICU discharge and beyond, with the total participation lasting up to several months depending on individual outcomes.
Actively Recruiting
Researchers are evaluating the effect of spironolactone combined with standard care compared to standard care alone in patients with Heart Failure with Preserved Ejection Fraction HFPEF. This condition is common and serious, but currently lacks effective treatment. The trial is a phase 3 Registry-Randomized Clinical Trial RRCT involving patients from the Swedish Heart Failure Registry and the US. HFPEF is defined by heart failure symptoms, elevated NT-proBNP levels, and an ejection fraction of 40% or higher. Participants will be randomly assigned to receive either spironolactone added to their usual care or usual care alone. Spironolactone will be given as 25 mg tablets, starting at 25 mg per day with a possible increase to 50 mg daily if tolerated. If spironolactone is not tolerated, eplerenone may be prescribed instead. The control group will continue with their standard care without spironolactone. The study duration is planned for 9 years, with enrollment lasting 7 years. During the study, researchers will collect data on cardiovascular death and hospitalizations due to heart failure as the primary outcomes. Secondary outcomes include hospitalizations for various causes, adverse events, and treatment adherence. In Sweden, outcomes will be obtained by linking national registries, while in the US, sites and call centers will report outcomes. The trial aims to enroll approximately 2000 patients, with follow-up continuing for at least 5 years after study start to monitor these outcomes.
Actively Recruiting
This research aims to evaluate pregnancy and infant outcomes in women exposed to anifrolumab, a drug used in treating systemic lupus erythematosus SLE. The study collects enhanced data from reported anifrolumab-exposed pregnancies as part of AstraZenecas pharmacovigilance system to better understand the safety of this drug during pregnancy. It focuses on the effects of anifrolumab exposure from 16 weeks before conception through pregnancy and up to 12 months after birth. The program gathers initial pregnancy information from reports submitted by patients or healthcare professionals to AstraZenecas database. Pregnancy outcomes are collected near the time of delivery, with additional follow-up assessments conducted 12 months after birth. For cases where pregnancy outcomes occurred before reporting, retrospective data including pregnancy and infant health details are collected at the time of report. The study uses targeted checklists and guidance to ensure comprehensive and standardized safety data collection for analysis. Participants provide information about their pregnancies and infant health through submitted reports and follow-up contacts. Researchers evaluate major and minor congenital malformations, adverse pregnancy outcomes, and the frequency of these events from conception to 12 months of infant age. The study continues monitoring the collected data until April 2031 to provide ongoing safety information about anifrolumab exposure during pregnancy and its effects on infants.